Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Glucocorticoid-induced osteoporosis

B H Hahn¹, E L Mazzaferri

¹University of California School of Medicine, Los Angeles, USA.

Hospital Practice (1995)

|August 15, 1995

Summary

High-dose medication over three months significantly reduces bone mass in all patients. Bone loss is rapid initially, so preventive measures like calcium, vitamin D, bisphosphonates, and exercise should start early in treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Attraction of mosquitoes to primate odours and implications for zoonotic Plasmodium transmission.

Medical and veterinary entomology·2019

Same author

Oral administration of different forms of a tolerogenic peptide to define the preparations and doses that delay anti-DNA antibody production and nephritis and prolong survival in SLE-prone mice.

Lupus·2011

Same author

Galectin-1-induced down-regulation of T lymphocyte activation protects (NZB x NZW) F1 mice from lupus-like disease.

Lupus·2011

Same author

Interferon-inducible gene 202b controls CD8(+) T cell-mediated suppression in anti-DNA Ig peptide-treated (NZB × NZW) F1 lupus mice.

Genes and immunity·2011

Same author

Thyroid cancer epidemiology and prognostic variables.

Clinical oncology (Royal College of Radiologists (Great Britain))·2010

Same author

Pro-inflammatory high-density lipoproteins and atherosclerosis are induced in lupus-prone mice by a high-fat diet and leptin.

Lupus·2010

Area of Science:

Pharmacology and Bone Metabolism
Endocrinology

Background:

Long-term, high-dose medication regimens are common in treating various chronic conditions.
Bone health is a critical factor in patient well-being and treatment adherence.

Observation:

Bone mass reduction occurs with high-dose treatment exceeding three months.
The rate of bone loss is most pronounced within the initial six to twelve months of therapy.

Findings:

Bone loss is independent of patient demographics such as age, sex, or race.
Prophylactic interventions are crucial for mitigating treatment-induced bone loss.

Implications:

Early initiation of bone-preserving strategies (calcium, vitamin D, bisphosphonates, exercise) is vital.
Clinical guidelines should emphasize proactive bone health management alongside disease treatment.

Related Experiment Videos